SLI
1.955,40
PKT
-7,42
PKT
-0,38
%
Werbung
Analysen zu SLI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
23.04.14 | Novartis buy | Société Générale Group S.A. (SG) | |
23.04.14 | Novartis buy | S&P Capital IQ | |
23.04.14 | Novartis Underweight | Barclays Capital | |
23.04.14 | Novartis buy | UBS AG | |
23.04.14 | Novartis Hold | Deutsche Bank AG | |
22.04.14 | UBS buy | S&P Capital IQ | |
22.04.14 | Novartis Neutral | JP Morgan Chase & Co. | |
17.04.14 | UBS buy | Citigroup Corp. | |
17.04.14 | UBS Hold | Kelper Cheuvreux | |
17.04.14 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
17.04.14 | Novartis Neutral | JP Morgan Chase & Co. | |
17.04.14 | UBS buy | UBS AG | |
17.04.14 | Novartis buy | UBS AG | |
16.04.14 | Roche buy | Citigroup Corp. | |
16.04.14 | Nestlé Halten | Independent Research GmbH | |
16.04.14 | Roche overweight | JP Morgan Chase & Co. | |
16.04.14 | Novartis Neutral | Goldman Sachs Group Inc. | |
16.04.14 | Roche overweight | Morgan Stanley | |
16.04.14 | Nestlé overweight | Morgan Stanley | |
16.04.14 | Nestlé Neutral | UBS AG | |
16.04.14 | Roche buy | UBS AG | |
16.04.14 | Roche overweight | Barclays Capital | |
15.04.14 | Nestlé Sell | S&P Capital IQ | |
15.04.14 | Roche kaufen | Independent Research GmbH | |
15.04.14 | Givaudan Outperform | Credit Suisse Group | |
15.04.14 | UBS Neutral | Goldman Sachs Group Inc. | |
15.04.14 | UBS buy | Goldman Sachs Group Inc. | |
14.04.14 | Roche buy | Jefferies & Company Inc. | |
14.04.14 | Novartis Hold | Jefferies & Company Inc. | |
14.04.14 | Givaudan overweight | JP Morgan Chase & Co. | |
14.04.14 | Nestlé overweight | JP Morgan Chase & Co. | |
14.04.14 | Givaudan Underweight | Barclays Capital | |
14.04.14 | Givaudan Underweight | Barclays Capital | |
14.04.14 | Givaudan buy | UBS AG | |
11.04.14 | Givaudan Neutral | Merrill Lynch & Co., Inc. | |
11.04.14 | Holcim buy | UBS AG | |
11.04.14 | Holcim buy | UBS AG | |
11.04.14 | UBS buy | UBS AG | |
11.04.14 | Roche buy | UBS AG | |
11.04.14 | UBS neutral | Deutsche Bank AG |